These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1633300)

  • 41. Interleukin-2 receptor-directed therapies: antibody-or cytokine-based targeting molecules.
    Strom TB; Kelley VR; Murphy JR; Nichols J; Woodworth TG
    Annu Rev Med; 1993; 44():343-53. PubMed ID: 8476255
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patents on immunotoxins and chimeric toxins for the treatment of cancer.
    Bachran C; Sutherland M; Bachran D; Fuchs H
    Recent Pat Drug Deliv Formul; 2007; 1(2):105-15. PubMed ID: 19075878
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeted therapy to the IL-2R using diphtheria toxin and caspase-3 fusion proteins modulates Treg and ameliorates inflammatory colitis.
    Yarkoni S; Sagiv Y; Kaminitz A; Farkas DL; Askenasy N
    Eur J Immunol; 2009 Oct; 39(10):2850-64. PubMed ID: 19735074
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Generation of chimeric toxins.
    FitzGerald D; Chaudhary VK; Kreitman RJ; Siegall CB; Pastan I
    Targeted Diagn Ther; 1992; 7():447-62. PubMed ID: 1633306
    [No Abstract]   [Full Text] [Related]  

  • 45. Immunotoxins and cytokine toxin fusion proteins.
    Strom TB; Anderson PL; Rubin-Kelley VE; Williams DP; Kiyokawa T; Murphy JR
    Ann N Y Acad Sci; 1991 Dec; 636():233-50. PubMed ID: 1793213
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of systemic mastocytosis with denileukin diftitox.
    Quintás-Cardama A; Kantarjian H; Verstovsek S
    Am J Hematol; 2007 Dec; 82(12):1124. PubMed ID: 17665501
    [No Abstract]   [Full Text] [Related]  

  • 47. Durable complete remission of mycosis fungoides following erythroderma induced by denileukin diftitox.
    Kazin R; Bujanauskas P; Vonderheid EC
    J Am Acad Dermatol; 2008 Feb; 58(2 Suppl):S31-2. PubMed ID: 18191695
    [No Abstract]   [Full Text] [Related]  

  • 48. Chimeric cytotoxin IL2-PE40 inhibits relapsing experimental allergic encephalomyelitis.
    Rose JW; Lorberboum-Galski H; Fitzgerald D; McCarron R; Hill KE; Townsend JJ; Pastan I
    J Neuroimmunol; 1991 Jun; 32(3):209-17. PubMed ID: 1709644
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diphtheria toxin fusion proteins.
    Foss FM; Saleh MN; Krueger JG; Nichols JC; Murphy JR
    Curr Top Microbiol Immunol; 1998; 234():63-81. PubMed ID: 9670613
    [No Abstract]   [Full Text] [Related]  

  • 50. Targeted toxin therapy for the treatment of cancer.
    FitzGerald D; Pastan I
    J Natl Cancer Inst; 1989 Oct; 81(19):1455-63. PubMed ID: 2550658
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diphtheria toxin-based targeted toxin therapy for brain tumors.
    Li YM; Vallera DA; Hall WA
    J Neurooncol; 2013 Sep; 114(2):155-64. PubMed ID: 23695514
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Advances in the treatment of non-Hodgkin lymphoma: interleukin-2 fusion toxin. A review of selected abstracts from the 2004 Annual Meeting of the American Society of Hematology. December 4-7, 2004, San Diego, California.
    Clin Adv Hematol Oncol; 2005 Mar; 3(3 Suppl 2):1-5; discussion 6-7. PubMed ID: 21434476
    [No Abstract]   [Full Text] [Related]  

  • 53. Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases.
    Lorberboum-Galski H
    Expert Opin Drug Deliv; 2011 May; 8(5):605-21. PubMed ID: 21453191
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Overcoming immunosuppressive mechanisms.
    Widén K; Mozaffari F; Choudhury A; Mellstedt H
    Ann Oncol; 2008 Sep; 19 Suppl 7():vii241-7. PubMed ID: 18790959
    [No Abstract]   [Full Text] [Related]  

  • 55. Receptor-directed chimeric toxins created by sortase-mediated protein fusion.
    McCluskey AJ; Collier RJ
    Mol Cancer Ther; 2013 Oct; 12(10):2273-81. PubMed ID: 23945077
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor.
    LeMaistre CF; Meneghetti C; Rosenblum M; Reuben J; Parker K; Shaw J; Deisseroth A; Woodworth T; Parkinson DR
    Blood; 1992 May; 79(10):2547-54. PubMed ID: 1586707
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination fusion protein therapy of refractory brain tumors: demonstration of efficacy in cell culture.
    Liu TF; Cohen KA; Willingham MC; Tatter SB; Puri RK; Frankel AE
    J Neurooncol; 2003 Oct; 65(1):77-85. PubMed ID: 14649887
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New monoclonal antibodies for hematologic malignancies (and breast cancer).
    Curtis MA
    Med Health R I; 2003 Aug; 86(8):256-7. PubMed ID: 14582224
    [No Abstract]   [Full Text] [Related]  

  • 59. Single-chain fusion toxins for the treatment of breast cancer: antitumor activity of BR96 sFv-PE40 and heregulin-PE40.
    Siegall CB
    Recent Results Cancer Res; 1996; 140():51-60. PubMed ID: 8787077
    [No Abstract]   [Full Text] [Related]  

  • 60. Hosts and Heterologous Expression Strategies of Recombinant Toxins for Therapeutic Purposes.
    di Leandro L; Colasante M; Pitari G; Ippoliti R
    Toxins (Basel); 2023 Dec; 15(12):. PubMed ID: 38133203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.